Australia, May 2 -- Bridgebio Pharma Inc., owns the trademark (2622871) for 'KALSTEDI' till Dec. 22, 2035.
Status: protected:
Registered/protected
Class: 5 [Pharmaceutical preparations for the treatment of endocrine and respiratory diseases and disorders, including autosomal dominant hypocalcemia type 1, hypoparathyroidism, and eosinophilic asthma.]
Type of Mark: Word
Date of Acceptance: Feb. 23
Registration Advertised: May 1
For further details contact Jessica L. Rothstein Goodwin Procter LLP .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2622871.
Disclaimer: Curated by HT Syndication....